Insider Trading April 6, 2026

Lands' End Director Sells 840 Shares Amid $45 Tender Offer; Q4 Results Miss Estimates

John McClain disposed of stock under a WH Topco subsidiary tender offer as the company reported a slight earnings and revenue shortfall and approved a $100 million buyback plan

By Leila Farooq LE
Lands' End Director Sells 840 Shares Amid $45 Tender Offer; Q4 Results Miss Estimates
LE

Director John McClain reported the sale of 840 shares of Lands' End common stock on April 1, 2026, in a Form 4 filing with the SEC. The shares were sold at $45.00 each under a tender offer from LEWHP, LLC - a wholly owned indirect subsidiary of WH Topco, L.P. The transaction totaled $37,800. Lands' End's recent fourth-quarter fiscal 2025 results fell short of consensus on both earnings per share and revenue, though total revenue rose 5% year-over-year. The board has also authorized a share repurchase program of up to $100 million through March 31, 2029.

Key Points

  • Director John McClain sold 840 Lands' End shares on April 1, 2026, at $45.00 per share, totaling $37,800 according to a Form 4 filing.
  • The sale was made under a tender offer from LEWHP, LLC - a wholly owned indirect subsidiary of WH Topco, L.P. - to acquire up to 2,222,222 shares at $45.00 each.
  • Lands' End's Q4 fiscal 2025 results showed EPS of $0.76 and revenue of $462.4 million, both below consensus; total revenue rose 5% year-over-year, and the board authorized a $100 million buyback through March 31, 2029.

According to a Form 4 filing submitted to the Securities and Exchange Commission, Lands' End, Inc. (NASDAQ:LE) director John McClain sold 840 shares of the company's common stock on April 1, 2026. The sale price recorded on the filing was $45.00 per share, producing a gross transaction value of $37,800.

The filing specifies the breakdown of holdings sold: 832 of the shares were disposed of from indirect holdings in an IRA, while the remaining 8 shares were held directly. After the transactions, McClain continues to hold 10,122 shares indirectly through the IRA and 92 shares held directly.

The sales were carried out pursuant to a tender offer launched by LEWHP, LLC, which is described in the filing as a wholly owned indirect subsidiary of WH Topco, L.P. The tender offer is structured to acquire up to 2,222,222 outstanding shares of the registrant's common stock at a cash price of $45.00 per share.

The $45.00 tender price represents a substantial premium relative to the current market trading price cited in the filing, $10.90 per share. The filing also references InvestingPro analysis indicating the stock is undervalued at the market price, assigning a Fair Value estimate of $14.90 per share.


In corporate results disclosed for the fourth quarter of fiscal 2025, Lands' End reported earnings per share of $0.76, below the forecasted $0.79. Revenue for the quarter totaled $462.4 million, missing the anticipated $472.24 million. Despite the misses versus expectations, the company noted that total revenue increased 5% compared with the same period in the prior year.

Board actions reported alongside the financials include authorization of a share repurchase program with a maximum ceiling of $100 million of common stock, which will remain open through March 31, 2029. The company indicated it may execute repurchases through open-market purchases, privately negotiated transactions, or other permitted methods consistent with federal securities laws.

These developments - the insider sale under the tender offer, the quarterly results that fell short of expectations, and the board-approved buyback authorization - were highlighted in the filing and related disclosures filed with regulators.


Key points:

  • Director John McClain sold 840 shares at $45.00 per share on April 1, 2026, via a Form 4 filing.
  • The sale was executed under a tender offer from LEWHP, LLC to purchase up to 2,222,222 shares at $45.00 each.
  • Lands' End reported Q4 fiscal 2025 EPS of $0.76 and revenue of $462.4 million, missing respective expectations of $0.79 and $472.24 million; total revenue rose 5% year-over-year.

Risks and uncertainties:

  • Earnings and revenue misses relative to forecasts could affect investor sentiment and equity valuation - impacting equity markets and investors in the company's stock.
  • The ultimate effect and pace of the authorized $100 million share repurchase program depend on future execution decisions and market conditions - influencing capital allocation outcomes for shareholders.
  • The tender offer dynamics, including decisions by other holders to tender shares, introduce uncertainty around ownership changes and potential impacts on the company's shareholder base.

Risks

  • Quarterly earnings and revenue fell short of expectations, which could weigh on investor confidence and equity performance in the company's shares.
  • Execution and timing of the $100 million share repurchase program are uncertain, leaving open how capital will be allocated and the potential market impact.
  • The tender offer to acquire up to 2,222,222 shares at $45.00 each creates uncertainty about future ownership composition and related market dynamics.

More from Insider Trading

Lipocine Director Purchases 123,000 Shares Amid Mixed Clinical News Apr 6, 2026 Kinder Morgan Vice President Disposes of $203K in Class P Shares Apr 6, 2026 RA Capital Disposes $14.5M of Vor Biopharma Stock Across Early April Trades Apr 6, 2026 Magnetar Financial Disposes of 23,088 Wheeler Real Estate Shares for About $21.5k Apr 6, 2026 Lipocine CEO Mahesh Patel Buys $50,749 of Stock as Company Reports Phase 3 Setback Apr 6, 2026